Malignant melanoma of gingiva: Report of a rare case.

Indian J Dent

Department of Oral Pathology and Microbiology, Bharati Vidyapeeth University Dental College and Hospital, Pune, Maharashtra, India.

Published: September 2015

According to the World Health Organization, oral malignant melanoma (OMM) is a rare disease, accounting for only 0.8% of all melanomas, 8% of head and neck melanomas, and up to 0.5% of all oral malignancies. OMM presents as a pigmented lesion with asymmetrical borders, irregular surface characteristics, and a distinct color. Melanoma-associated pigmented lesion of the oral cavity does not possess clinical specificity and frequently divert the clinical diagnosis; hence, differential diagnosis becomes mandatory. Furthermore, the unpredictable pathophysiological behavior and delayed detection, contributes for poor prognosis of the disease. As a result, the 5 years survival rate is only 10-25%. Commonly OMM is seen in maxillary gingiva of males. However, we report a rare case of a middle-aged female having pigmentations and growth over mandibular gingiva.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558754PMC
http://dx.doi.org/10.4103/0975-962X.163052DOI Listing

Publication Analysis

Top Keywords

malignant melanoma
8
report rare
8
rare case
8
pigmented lesion
8
melanoma gingiva
4
gingiva report
4
case health
4
health organization
4
organization oral
4
oral malignant
4

Similar Publications

With the continuous development of Terahertz technology and its high sensitivity to water, Terahertz technology has been widely applied in various research areas within the field of biomedicine, such as research onskin wounds and burns, demonstrating numerous advantages and potential. The aim of this study is to summarize and conclude the current research status of Terahertz radiation in skin wounds, burns, and melanoma. Additionally, it seeks toreveal the development status of Terahertz in skin wound models and analyze the short comings of Terahertz in detecting such models at the present stage.

View Article and Find Full Text PDF

BRAF mutations drive initiation and progression of various tumors. While BRAF inhibitors are effective in BRAF-mutant melanoma patients, intrinsic or acquired resistance to these therapies is common. Here, we identify non-receptor-type protein tyrosine phosphatase 23 (PTPN23) as an alternative effective target in BRAF-mutant cancer cells.

View Article and Find Full Text PDF

Background: Primary tumor thickness is important for prognosis of melanoma patients. To enhance prevention and quantify the true burden of melanoma, better understanding of thickness patterns and associated characteristics is crucial. Previous studies have been limited to report trends and address risk factors of thickness in specific melanoma subtypes in the Greek population.

View Article and Find Full Text PDF

Estimates of the burden of skin melanoma in Italy: update to 2024.

Ital J Dermatol Venerol

January 2025

Emilia-Romagna Cancer Registry, Romagna Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy.

Background: The epidemiology of skin melanoma (SM) is rapidly changing. Therefore, we aimed at updating up to 2024 the Italian estimates on SM providing the number of incident and prevalent cases, the deaths and the distribution by stage at diagnosis.

Methods: Incidence was extrapolated from age- and sex-specific International Agency for Research on Cancer (IARC) estimates from 2022 to 2025.

View Article and Find Full Text PDF

Objective: Sodium-glucose cotransporter (SGLT) 2 inhibitors are expected to demonstrate secondary effects against malignancy. However, long-term and large-scale data are required to evaluate the effects of SGLT2 inhibitors on malignancy, which has not been sufficiently studied in clinical practice. This study aimed to evaluate the association between SGLT2 inhibitors and malignancy using the spontaneous adverse reaction database.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!